Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Intensity Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 21 | 27 | +6 |
| Shares | 2.59M | 1.98M | −609.8K (−23.6%) |
| Value | $5.10M | $606.6K | −$4.49M (−88.1%) |
New holders (10)
Institutions that held Intensity Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Warberg Asset Management LLC | 68,400 | $21.0K | 0.01% |
| Jane Street Group, LLC | 44,897 | $13.8K | 0.00% |
| XTX Topco Ltd | 24,553 | $7.54K | 0.00% |
| HRT Financial LP | 24,904 | $7.00K | 0.00% |
| Ewa, LLC | 16,032 | $4.92K | 0.00% |
| Boothbay Fund Management, LLC | 15,000 | $4.61K | 0.00% |
| Virtu Financial LLC | 13,700 | $4.00K | 0.00% |
| Cubist Systematic Strategies, LLC | 11,673 | $3.58K | 0.00% |
| CIBC Private Wealth Group, LLC | 5,000 | $1.53K | 0.00% |
| FMR LLC | 100 | $31 | 0.00% |
Sold out (4)
Institutions that held Intensity Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Armistice Capital, LLC | 872,547 | $1.72M |
| Citadel Advisors LLC | 25,801 | $50.8K |
| BlackRock, Inc. | 21,835 | $43.0K |
| JPMorgan Chase & Co | 15 | $30 |